N
Nina Xue
Researcher at Peking Union Medical College
Publications - 37
Citations - 501
Nina Xue is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 11, co-authored 27 publications receiving 307 citations.
Papers
More filters
Journal ArticleDOI
Chlorogenic acid inhibits glioblastoma growth through repolarizating macrophage from M2 to M1 phenotype
Nina Xue,Qin Zhou,Ming Ji,Jing Jin,Fangfang Lai,Ju Chen,Zhang Mengtian,Jing Jia,Yang Huarong,Jie Zhang,Wenbin Li,Jian-Dong Jiang,Xiaoguang Chen +12 more
TL;DR: Findings indicated CHA as a potential therapeutic approach to reduce glioma growth through promoting M1-polarized macrophage and inhibiting M2 phenotypic macrophages.
Journal ArticleDOI
Chlorogenic acid effectively treats cancers through induction of cancer cell differentiation.
Shuai Huang,Lu-Lu Wang,Nina Xue,Cong Li,Hui-Hui Guo,Tian-Kun Ren,Yun Zhan,Wen-Bing Li,Zhang Jie,Xiaoguang Chen,Yan-Xing Han,Jinlan Zhang,Jian-Dong Jiang +12 more
TL;DR: Chlorogenic acid might be a safe and effective differentiation-inducer for cancer therapy and “Educating” cancer cells to differentiate, rather than killing them, could be a novel therapeutic strategy for cancer.
Journal ArticleDOI
Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
Kehui Zhang,Lai Fangfang,Songwen Lin,Ming Ji,Jingbo Zhang,Yan Zhang,Jing Jin,Rong Fu,Deyu Wu,Hua Tian,Nina Xue,Li Sheng,Xiaowen Zou,Yan Li,Xiaoguang Chen,Heng Xu +15 more
TL;DR: In this paper, a series of novel PI3K and HDAC dual inhibitors were discovered in which the hydroxamic acid moiety as the zinc binding functional group was introduced to a quinazoline-based PI3k pharmacophore through an appropriate linker.
Journal ArticleDOI
CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway.
Ju Chen,Haining Lv,Hu Jinping,Ming Ji,Nina Xue,Chao Li,Shuang-Gang Ma,Qin Zhou,Bin Lin,Yan Li,Shi-Shan Yu,Xiaoguang Chen +11 more
TL;DR: The hypothesis that CAT3 is a promising therapeutic agent for the treatment of Hh-driven MB and GBM is supported.
Journal ArticleDOI
Development of a selective S1P1 receptor agonist, Syl930, as a potential therapeutic agent for autoimmune encephalitis.
TL;DR: It is found that Syl930 can activate and internalize S1P1 receptors and effectively decreased the periphery blood lymphocytes (PBL) in SD rats, and subsequently rendered PBL insensitive to egress signal from secondary lymphoid organs (SLO).